Potential drug-drug interactions within Veterans Affairs medical centers

Maysaa Mahmood, Daniel C. Malone, Grant H. Skrepnek, Jacob Abarca, Edward P. Armstrong, John E. Murphy, Amy J. Grizzle, Yu Ko, Raymond L. Woosley

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose. This study assessed the prevalence of 25 clinically important drug-drug interactions (DDIs) in the ambulatory care clinics of the Department of Veterans Affairs medical centers (VAMCs). Methods. This study was a retrospective, cross-sectional database analysis of pharmacy records to assess the prevalence of 25 clinically important DDIs. For each DDI, the object drug was defined as the medication that has its therapeutic effect modified by the drug interaction process. The precipitant drug was defined as the medication responsible for affecting the pharmacologic action or the pharmacokinetic properties of the object drug. Rates of interactions for each VAMC facility were calculated as the number of patients with a DDI divided by the total number of individual patients exposed to the object or precipitant medications. The 25 DDIs were categorized into four main categories on the basis of the therapeutic classification of the medications involved in the drug pairs. Results. The study population included 2,795,345 patients who filled prescriptions for medications involved in potential DDIs across 128 VAMCs. The highest DDI exposure rate was 129.2 per 1,000 recipients of monoamine oxidase inhibitors (MAOIs) that occurred with combinations of selective serotonin-reuptake inhibitors (SSRIs). The lowest DDI exposure rate was 0.01 per 1,000 warfarin recipients who had the warfarin and sulfinpyrazone combination. Conclusion. The analysis of pharmacy records of veterans who filled prescriptions at the outpatient settings within VAMC found an overall rate of 2.15% for potential DDIs. Case-exposure rates were greatest for veterans receiving SSRIs and MAOIs, ganciclovir and zidovudine, anticoagulants and thyroid hormones, and warfarin and nonsteroidal antiinflammatory drugs.

Original languageEnglish
Pages (from-to)1500-1505
Number of pages6
JournalAmerican Journal of Health-System Pharmacy
Volume64
Issue number14
DOIs
Publication statusPublished - Jul 15 2007
Externally publishedYes

Fingerprint

Veterans
Drug Interactions
Pharmaceutical Preparations
Warfarin
Monoamine Oxidase Inhibitors
Serotonin Uptake Inhibitors
Prescriptions
Cross-Sectional Studies
Sulfinpyrazone
Pharmacologic Actions
Ganciclovir
Zidovudine
Therapeutic Uses
Ambulatory Care
Thyroid Hormones
Anticoagulants
Anti-Inflammatory Agents
Outpatients
Pharmacokinetics

Keywords

  • Anticoagulants
  • Antidepressants
  • Antiinflammatory agents
  • Antiretroviral agents
  • Antivirals
  • Drug interactions
  • Ganciclovir
  • Monoamine oxidase inhibitors
  • Pharmacokinetics
  • Prescriptions
  • Sulfinpyrazone
  • Thyroid drugs
  • Uricosuric agents
  • Warfarin
  • Zidovudine

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Leadership and Management

Cite this

Mahmood, M., Malone, D. C., Skrepnek, G. H., Abarca, J., Armstrong, E. P., Murphy, J. E., ... Woosley, R. L. (2007). Potential drug-drug interactions within Veterans Affairs medical centers. American Journal of Health-System Pharmacy, 64(14), 1500-1505. https://doi.org/10.2146/ajhp060548

Potential drug-drug interactions within Veterans Affairs medical centers. / Mahmood, Maysaa; Malone, Daniel C.; Skrepnek, Grant H.; Abarca, Jacob; Armstrong, Edward P.; Murphy, John E.; Grizzle, Amy J.; Ko, Yu; Woosley, Raymond L.

In: American Journal of Health-System Pharmacy, Vol. 64, No. 14, 15.07.2007, p. 1500-1505.

Research output: Contribution to journalArticle

Mahmood, M, Malone, DC, Skrepnek, GH, Abarca, J, Armstrong, EP, Murphy, JE, Grizzle, AJ, Ko, Y & Woosley, RL 2007, 'Potential drug-drug interactions within Veterans Affairs medical centers', American Journal of Health-System Pharmacy, vol. 64, no. 14, pp. 1500-1505. https://doi.org/10.2146/ajhp060548
Mahmood M, Malone DC, Skrepnek GH, Abarca J, Armstrong EP, Murphy JE et al. Potential drug-drug interactions within Veterans Affairs medical centers. American Journal of Health-System Pharmacy. 2007 Jul 15;64(14):1500-1505. https://doi.org/10.2146/ajhp060548
Mahmood, Maysaa ; Malone, Daniel C. ; Skrepnek, Grant H. ; Abarca, Jacob ; Armstrong, Edward P. ; Murphy, John E. ; Grizzle, Amy J. ; Ko, Yu ; Woosley, Raymond L. / Potential drug-drug interactions within Veterans Affairs medical centers. In: American Journal of Health-System Pharmacy. 2007 ; Vol. 64, No. 14. pp. 1500-1505.
@article{68f3a31437d648dda156f616061fb703,
title = "Potential drug-drug interactions within Veterans Affairs medical centers",
abstract = "Purpose. This study assessed the prevalence of 25 clinically important drug-drug interactions (DDIs) in the ambulatory care clinics of the Department of Veterans Affairs medical centers (VAMCs). Methods. This study was a retrospective, cross-sectional database analysis of pharmacy records to assess the prevalence of 25 clinically important DDIs. For each DDI, the object drug was defined as the medication that has its therapeutic effect modified by the drug interaction process. The precipitant drug was defined as the medication responsible for affecting the pharmacologic action or the pharmacokinetic properties of the object drug. Rates of interactions for each VAMC facility were calculated as the number of patients with a DDI divided by the total number of individual patients exposed to the object or precipitant medications. The 25 DDIs were categorized into four main categories on the basis of the therapeutic classification of the medications involved in the drug pairs. Results. The study population included 2,795,345 patients who filled prescriptions for medications involved in potential DDIs across 128 VAMCs. The highest DDI exposure rate was 129.2 per 1,000 recipients of monoamine oxidase inhibitors (MAOIs) that occurred with combinations of selective serotonin-reuptake inhibitors (SSRIs). The lowest DDI exposure rate was 0.01 per 1,000 warfarin recipients who had the warfarin and sulfinpyrazone combination. Conclusion. The analysis of pharmacy records of veterans who filled prescriptions at the outpatient settings within VAMC found an overall rate of 2.15{\%} for potential DDIs. Case-exposure rates were greatest for veterans receiving SSRIs and MAOIs, ganciclovir and zidovudine, anticoagulants and thyroid hormones, and warfarin and nonsteroidal antiinflammatory drugs.",
keywords = "Anticoagulants, Antidepressants, Antiinflammatory agents, Antiretroviral agents, Antivirals, Drug interactions, Ganciclovir, Monoamine oxidase inhibitors, Pharmacokinetics, Prescriptions, Sulfinpyrazone, Thyroid drugs, Uricosuric agents, Warfarin, Zidovudine",
author = "Maysaa Mahmood and Malone, {Daniel C.} and Skrepnek, {Grant H.} and Jacob Abarca and Armstrong, {Edward P.} and Murphy, {John E.} and Grizzle, {Amy J.} and Yu Ko and Woosley, {Raymond L.}",
year = "2007",
month = "7",
day = "15",
doi = "10.2146/ajhp060548",
language = "English",
volume = "64",
pages = "1500--1505",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "14",

}

TY - JOUR

T1 - Potential drug-drug interactions within Veterans Affairs medical centers

AU - Mahmood, Maysaa

AU - Malone, Daniel C.

AU - Skrepnek, Grant H.

AU - Abarca, Jacob

AU - Armstrong, Edward P.

AU - Murphy, John E.

AU - Grizzle, Amy J.

AU - Ko, Yu

AU - Woosley, Raymond L.

PY - 2007/7/15

Y1 - 2007/7/15

N2 - Purpose. This study assessed the prevalence of 25 clinically important drug-drug interactions (DDIs) in the ambulatory care clinics of the Department of Veterans Affairs medical centers (VAMCs). Methods. This study was a retrospective, cross-sectional database analysis of pharmacy records to assess the prevalence of 25 clinically important DDIs. For each DDI, the object drug was defined as the medication that has its therapeutic effect modified by the drug interaction process. The precipitant drug was defined as the medication responsible for affecting the pharmacologic action or the pharmacokinetic properties of the object drug. Rates of interactions for each VAMC facility were calculated as the number of patients with a DDI divided by the total number of individual patients exposed to the object or precipitant medications. The 25 DDIs were categorized into four main categories on the basis of the therapeutic classification of the medications involved in the drug pairs. Results. The study population included 2,795,345 patients who filled prescriptions for medications involved in potential DDIs across 128 VAMCs. The highest DDI exposure rate was 129.2 per 1,000 recipients of monoamine oxidase inhibitors (MAOIs) that occurred with combinations of selective serotonin-reuptake inhibitors (SSRIs). The lowest DDI exposure rate was 0.01 per 1,000 warfarin recipients who had the warfarin and sulfinpyrazone combination. Conclusion. The analysis of pharmacy records of veterans who filled prescriptions at the outpatient settings within VAMC found an overall rate of 2.15% for potential DDIs. Case-exposure rates were greatest for veterans receiving SSRIs and MAOIs, ganciclovir and zidovudine, anticoagulants and thyroid hormones, and warfarin and nonsteroidal antiinflammatory drugs.

AB - Purpose. This study assessed the prevalence of 25 clinically important drug-drug interactions (DDIs) in the ambulatory care clinics of the Department of Veterans Affairs medical centers (VAMCs). Methods. This study was a retrospective, cross-sectional database analysis of pharmacy records to assess the prevalence of 25 clinically important DDIs. For each DDI, the object drug was defined as the medication that has its therapeutic effect modified by the drug interaction process. The precipitant drug was defined as the medication responsible for affecting the pharmacologic action or the pharmacokinetic properties of the object drug. Rates of interactions for each VAMC facility were calculated as the number of patients with a DDI divided by the total number of individual patients exposed to the object or precipitant medications. The 25 DDIs were categorized into four main categories on the basis of the therapeutic classification of the medications involved in the drug pairs. Results. The study population included 2,795,345 patients who filled prescriptions for medications involved in potential DDIs across 128 VAMCs. The highest DDI exposure rate was 129.2 per 1,000 recipients of monoamine oxidase inhibitors (MAOIs) that occurred with combinations of selective serotonin-reuptake inhibitors (SSRIs). The lowest DDI exposure rate was 0.01 per 1,000 warfarin recipients who had the warfarin and sulfinpyrazone combination. Conclusion. The analysis of pharmacy records of veterans who filled prescriptions at the outpatient settings within VAMC found an overall rate of 2.15% for potential DDIs. Case-exposure rates were greatest for veterans receiving SSRIs and MAOIs, ganciclovir and zidovudine, anticoagulants and thyroid hormones, and warfarin and nonsteroidal antiinflammatory drugs.

KW - Anticoagulants

KW - Antidepressants

KW - Antiinflammatory agents

KW - Antiretroviral agents

KW - Antivirals

KW - Drug interactions

KW - Ganciclovir

KW - Monoamine oxidase inhibitors

KW - Pharmacokinetics

KW - Prescriptions

KW - Sulfinpyrazone

KW - Thyroid drugs

KW - Uricosuric agents

KW - Warfarin

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=34447545865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447545865&partnerID=8YFLogxK

U2 - 10.2146/ajhp060548

DO - 10.2146/ajhp060548

M3 - Article

VL - 64

SP - 1500

EP - 1505

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 14

ER -